GET DAILY SIGNALSDenali Therapeutics (DNLI): Q3 Momentum Builds for AVLAYAH and Pipeline Milestones
Key Takeaways
- DNLI traded near $19.87 in early November, up roughly 2% over the trailing 30 days from about $19.45 in early October, a modest move below the 10% threshold.
- Third-quarter 2026 results showed AVLAYAH (tividenofusp alfa) net product revenue of $17.8 million in its second full commercial quarter, with Q4 2026 guidance of $30.0 million to $32.0 million.
- The company reported Q3 GAAP EPS of $0.37 and net income of $70.1 million, lifted by a one-time roughly $194 million gain from the sale of a Priority Review Voucher.
- Analyst sentiment remains constructive: consensus rating of "Strong Buy" with average 12-month price targets in the mid-$30s, and Guggenheim reiterated DNLI as a top pick after results.
- Near-term catalysts include December 2026 Phase II MoMeNtum data in multifocal motor neuropathy and continued execution on AVLAYAH reimbursement and launch uptake.
- The broader trend is mixed: shares are up about 35% over the past year but down double digits over the trailing three months.
- For additional detail on this ticker, explore Price Targets, Earnings, and Forecast pages.
- Discover how automated strategies are tracking this and other names through Trending AI Robots.
Current Market Snapshot
Denali Therapeutics shares have moved within a fairly tight range over the past month, staying between the high teens and low $20s. The stock saw a bump after its third-quarter report in early November but still sits well below its 52-week peak. With a market cap around $3.1 billion, DNLI draws attention mainly for its blood-brain barrier platform and the rollout of its first approved therapy rather than near-term profits. Over the past year the shares have climbed about 35%, though they have slipped by double digits in the last three months, which is common in this sector.
Denali Therapeutics (DNLI) Business Overview and Competitive Position
Denali Therapeutics is a South San Francisco biopharmaceutical firm focused on treatments for neurodegenerative and lysosomal storage diseases. Its main edge comes from Transport Vehicle technology aimed at getting large-molecule therapies across the blood-brain barrier, a longstanding challenge in the field. The company works across three areas: Enzyme TV, Oligonucleotide TV, and Antibody TV.
The lead program is AVLAYAH (tividenofusp alfa), an enzyme replacement therapy that earned FDA accelerated approval in March 2026 for the neurologic effects of Hunter syndrome. It marks the first approved therapy using transferrin-receptor delivery across the blood-brain barrier. The pipeline also covers programs in Sanfilippo syndrome type A, frontotemporal dementia, Alzheimer’s, Parkinson’s, and Pompe disease. Investors track DNLI for the mix of a newly commercial product and a broad neurology pipeline. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.
Recent Developments Driving DNLI
Third-quarter 2026 results, released on November 3, stood out as the main event. AVLAYAH brought in $17.8 million in net product revenue during its second full commercial quarter, and management guided fourth-quarter net product revenue to $30.0 million to $32.0 million. The company posted GAAP EPS of $0.37 and net income of $70.1 million, helped by a one-time gain of roughly $194 million from selling a rare pediatric disease Priority Review Voucher.
Reimbursement progress has helped support the launch. Commercial coverage now reaches more than 70% of U.S. commercial insured lives, up from over 50% the prior quarter, and a permanent J-code took effect on October 1, 2026, easing billing. In late October, AVLAYAH received a 2026 Prix Galien USA award as Best Biotechnology Product.
Analyst notes after the report have been supportive overall. Guggenheim kept DNLI as a top pick with a Buy rating, and other firms reaffirmed Buy ratings with targets well above the current price. The company closed the quarter with about $1.0 billion in cash and marketable securities, giving it a solid runway for ongoing programs.
2026 Outlook and What Investors Should Watch
Looking forward, the next key event is the December 2026 top-line data from the Phase II MoMeNtum study of claseprubart in multifocal motor neuropathy. Tracking AVLAYAH’s commercial progress, including the fourth-quarter revenue guidance, will also be important to gauge launch traction and reimbursement gains.
Into 2027, attention will likely turn to the planned Biologics License Application for zafinofusp alfa in Sanfilippo syndrome type A, early data from the Phase I DNTH212 study in the first quarter, and top-line results from Part A of the Phase III CAPTIVATE study in chronic inflammatory demyelinating polyneuropathy late in the year. Broader economic conditions, trial outcomes, and competition in rare-disease neurology will remain factors that shape sentiment. These are considerations for monitoring rather than specific recommendations.
Exploring Systematic Approaches with Tickeron Tools
In my research on names like DNLI, I find it useful to review how automated models are positioned. Tickeron’s Trending AI Robots page curates top-performing strategies from hundreds of AI-powered bots across thousands of tickers. It lets users compare different timeframes and risk profiles to see which approaches align with their own style, offering a practical way to explore data-driven ideas without replacing personal analysis.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Contributor
I’m a trader and independent researcher. My interest lies at the intersection of financial markets, algorithms, and capital management. I develop data-driven tools and strategies and study algorithmic approaches to market analysis. I help turn complex market data into clear insights and practical systems. I believe technology should support, not replace, investment thinking
DNLI's RSI Oscillator recovers from oversold territory
The RSI Indicator for DNLI moved out of oversold territory on October 19, 2026. This could be a sign that the stock is shifting from a downward trend to an upward trend. Traders may want to buy the stock or call options. The A.I.dvisor looked at 26 similar instances when the indicator left oversold territory. In 21 of the 26 cases the stock moved higher. This puts the odds of a move higher at 81%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The Momentum Indicator moved above the 0 level on October 27, 2026. You may want to consider a long position or call options on DNLI as a result. In 65 of 91 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 71%.
The Moving Average Convergence Divergence (MACD) for DNLI just turned positive on October 20, 2026. Looking at past instances where DNLI's MACD turned positive, the stock continued to rise in 39 of 51 cases over the following month. The odds of a continued upward trend are 76%.
Following a +3.09% 3-day Advance, the price is estimated to grow further. Considering data from situations where DNLI advanced for three days, in 206 of 263 cases, the price rose further within the following month. The odds of a continued upward trend are 78%.
Bearish Trend Analysis
The Stochastic Oscillator may be shifting from an upward trend to a downward trend. In 53 of 62 cases where DNLI's Stochastic Oscillator exited the overbought zone, the price fell further within the following month. The odds of a continued downward trend are 85%.
DNLI moved below its 50-day moving average on November 10, 2026 date and that indicates a change from an upward trend to a downward trend.
The 50-day moving average for DNLI moved below the 200-day moving average on October 26, 2026. This could be a long-term bearish signal for the stock as the stock shifts to an downward trend.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where DNLI declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 82%.
DNLI broke above its upper Bollinger Band on November 04, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
The Aroon Indicator for DNLI entered a downward trend on October 28, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron PE Growth Rating for this company is 30 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Price Growth Rating for this company is 50 (best 1 - 100 worst), indicating steady price growth. DNLI’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Valuation Rating of 82 (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (3.841) is normal, around the industry mean (3.498). P/E Ratio (-7.067) is within average values for comparable stocks, (-1.193). Projected Growth (PEG Ratio) (2.300) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (130.981) among similar stocks. P/S Ratio (1000.000) is also within normal values, averaging (440.869).
The Tickeron SMR rating for this company is 98 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. DNLI’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 93, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
a biotechnology company
Industry Biotechnology
Advertisement